Compare LSBK & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | STIM |
|---|---|---|
| Founded | 1891 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 120.4M |
| IPO Year | 2025 | 2018 |
| Metric | LSBK | STIM |
|---|---|---|
| Price | $17.72 | $1.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 25.4K | ★ 806.2K |
| Earning Date | 10-26-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | 49.23 | ★ 57.25 |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | N/A | $8.63 |
| Revenue Next Year | N/A | $9.24 |
| P/E Ratio | $30.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $0.80 |
| 52 Week High | $19.09 | $3.44 |
| Indicator | LSBK | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 23.13 |
| Support Level | $16.89 | $1.19 |
| Resistance Level | $18.93 | $2.13 |
| Average True Range (ATR) | 0.59 | 0.12 |
| MACD | -0.10 | -0.05 |
| Stochastic Oscillator | 52.78 | 2.60 |
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.